PharmaShots | Incisive News in 3 Shots

Subscribe Now

brca-mutated advanced ovarian cancer

AstraZeneca and MSD's Lynparza (olaparib) Receive NMPA's Approval as 1L Maintenance Therapy for BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and MSD's Lynparza (olaparib) Receive NMPA's Approval as 1L Maintenance Therapy for BRCA-Mutated Advanced Ovarian Canc...

December 5, 2019

AstraZeneca and Merck's Lynparza (olaparib) Receives FDA's Approval for 1L BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and Merck's Lynparza (olaparib) Receives FDA's Approval for 1L BRCA-Mutated Advanced Ovarian Cancer

December 20, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us